HER2 Negative Breast Cancer Overview
Learn About HER2 Negative Breast Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
New York University
Freya Schnabel is a General Surgeon in New York, New York. Dr. Schnabel has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Intraductal Papilloma, Giant Mammary Hamartoma, Mastectomy, and Lymphadenectomy.
New York University
Deborah Axelrod is a Surgical Oncologist and a General Surgeon in New York, New York. Dr. Axelrod and is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Fibrocystic Breast Disease, Breast Infection, Mastectomy, and Lymphadenectomy.
New York University
Leslie Boyd is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New York, New York. Dr. Boyd and is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.
Summary: This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole. This study aims to evaluate whether chemotherapy could be avoided for initial high-risk clinicopathol...
Summary: This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.